Adult Acute Lymphocytic Leukemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Adult Acute Lymphocytic Leukemia

MalaCards integrated aliases for Adult Acute Lymphocytic Leukemia:

Name: Adult Acute Lymphocytic Leukemia 12 54 15 37 71
Adult Acute Lymphoid Leukemia 12
Adult All 12


External Ids:

Disease Ontology 12 DOID:5604
NCIt 49 C4967
UMLS 71 C0751606

Summaries for Adult Acute Lymphocytic Leukemia

Disease Ontology : 12 An acute lymphocytic leukemia occurring during adulthood.

MalaCards based summary : Adult Acute Lymphocytic Leukemia, also known as adult acute lymphoid leukemia, is related to t-cell adult acute lymphocytic leukemia and b-cell adult acute lymphocytic leukemia. An important gene associated with Adult Acute Lymphocytic Leukemia is SHMT1 (Serine Hydroxymethyltransferase 1), and among its related pathways/superpathways are One carbon pool by folate and Hematopoietic cell lineage. The drugs Cladribine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Adult Acute Lymphocytic Leukemia

Diseases in the Leukemia, Chronic Lymphocytic family:

Leukemia, Chronic Lymphocytic 2 Leukemia, Chronic Lymphocytic 1
Leukemia, Chronic Lymphocytic 3 Leukemia, Chronic Lymphocytic 4
Leukemia, Chronic Lymphocytic 5 Adult Acute Lymphocytic Leukemia

Diseases related to Adult Acute Lymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
# Related Disease Score Top Affiliating Genes
1 t-cell adult acute lymphocytic leukemia 34.6 HBZ CD7 CD4 CCR6
2 b-cell adult acute lymphocytic leukemia 34.3 PBX1 IKZF1 CD19 ABL1
3 t-cell acute lymphoblastic leukemia 31.8 IKZF1 ETV6 CDKN2B ABL1
4 burkitt lymphoma 31.6 TP73 CSF3 CDKN2B CD19 ABL1
5 leukemia 30.8 PBX1 MTHFR IKZF1 ETV6 AFF1 ABL1
6 mucositis 30.7 TYMS MTHFR CSF3
7 lymphoblastic lymphoma 30.3 CDKN2B CD7 CD4
8 acute leukemia 30.2 MTHFR ETV6 CSF3 CDKN2B CD7 AFF1
9 leukemia, acute lymphoblastic 3 29.9 PBX1 IKZF1 ETV6 CDKN2B CD19 AFF1
10 severe combined immunodeficiency 29.9 CSF3 CD7 CD4 CD19 CCR6
11 precursor t-cell acute lymphoblastic leukemia 29.9 IKZF1 ETV6 CDKN2B CD7 ABL1
12 exanthem 29.9 CSF3 CD4 CCR6
13 myeloma, multiple 29.8 IKZF1 CSF3 CD4 CD19 CCR6 ABL1
14 leukemia, chronic myeloid 29.6 IKZF1 ETV6 CSF3 CDKN2B CDKN1C CD19
15 lymphoma, non-hodgkin, familial 29.4 IKZF1 ETV6 CSF3 CDKN2B CD7 CD4
16 leukemia, acute myeloid 28.6 PBX1 IKZF1 ETV6 CSF3 CDKN2B CD7
17 leukemia, acute lymphoblastic 28.3 TYMS TP73 PBX1 MTHFR IKZF1 HBZ
18 hemifacial spasm 10.6 TYMS MTHFR
19 homocystinuria due to deficiency of n -methylenetetrahydrofolate reductase activity 10.6 MTR MTHFR
20 methotrexate toxicity 10.5 TYMS MTR MTHFR
21 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 10.5 IKZF1 ABL1
22 pediatric osteosarcoma 10.5 SHMT1 MTR MTHFR
23 pyomyositis 10.5 CSF3 CD4
24 otosalpingitis 10.5 CSF3 CD19
25 mental retardation, autosomal dominant 29 10.5 PBX1 ABL1
26 mucormycosis 10.5 CSF3 CD4 CCR6
27 scabies 10.5 CSF3 CD4 CCR6
28 pneumocystosis 10.5 CSF3 CD4 CCR6
29 autoimmune disease of cardiovascular system 10.4 MTHFR CD4 CCR6
30 lobomycosis 10.4 CD4 CD19
31 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 10.4 ETV6 ABL1
32 mental retardation, autosomal dominant 33 10.4 IKZF1 ETV6 ABL1
33 parapsoriasis 10.4 CD7 CD4
34 b-lymphoblastic leukemia/lymphoma with hypodiploidy 10.4 PBX1 ETV6 ABL1
35 invasive aspergillosis 10.4 CSF3 CD4 CCR6
36 b-lymphoblastic leukemia/lymphoma with hyperdiploidy 10.4 PBX1 ETV6 ABL1
37 opportunistic mycosis 10.4 CSF3 CD4 CCR6
38 fungal infectious disease 10.4 CSF3 CD4 CCR6
39 vein disease 10.4 MTHFR CD4 CCR6
40 testicular leukemia 10.4 ETV6 ABL1
41 eye lymphoma 10.4 CD4 CD19
42 blood protein disease 10.4 MTHFR CD19 CCR6
43 hemorrhagic cystitis 10.4 CSF3 CD4 CD19
44 bacterial pneumonia 10.4 CSF3 CD4 CCR6
45 follicular mucinosis 10.4 CD7 CD4
46 anauxetic dysplasia 1 10.4 CSF3 CD19
47 spongiotic dermatitis 10.4 CD7 CD4
48 hair disease 10.4 CSF3 CD4 CCR6
49 cd40 ligand deficiency 10.4 CSF3 CD4 CD19
50 strongyloidiasis 10.4 HBZ CD7 CD4

Graphical network of the top 20 diseases related to Adult Acute Lymphocytic Leukemia:

Diseases related to Adult Acute Lymphocytic Leukemia

Symptoms & Phenotypes for Adult Acute Lymphocytic Leukemia

GenomeRNAi Phenotypes related to Adult Acute Lymphocytic Leukemia according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.98 ABL1
2 Decreased viability GR00221-A-2 9.98 ABL1 CDKN1C
3 Decreased viability GR00221-A-3 9.98 ABL1 CDKN1C
4 Decreased viability GR00221-A-4 9.98 CDKN1C
5 Decreased viability GR00240-S-1 9.98 ABCG2
6 Decreased viability GR00249-S 9.98 CD19 PBX1 TP73
7 Decreased viability GR00301-A 9.98 CDKN1C
8 Decreased viability GR00342-S-1 9.98 ABL1
9 Decreased viability GR00342-S-2 9.98 ABL1 CD4
10 Decreased viability GR00342-S-3 9.98 ABL1
11 Decreased viability GR00381-A-1 9.98 AFF1 CD19
12 Decreased viability GR00386-A-1 9.98 CSF3 MTHFR TYMS
13 Decreased viability GR00402-S-2 9.98 TP73
14 Reduced mammosphere formation GR00396-S 9.17 CCR6 CD7 CDX4 CSF3 ETV6 IKZF1

MGI Mouse Phenotypes related to Adult Acute Lymphocytic Leukemia:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.24 ABCG2 ABL1 AFF1 CCR6 CD19 CD4
2 homeostasis/metabolism MP:0005376 10.13 ABCG2 ABL1 CCR6 CD19 CD4 CDKN2B
3 immune system MP:0005387 10.07 ABCG2 ABL1 AFF1 CCR6 CD19 CD4
4 endocrine/exocrine gland MP:0005379 10.06 ABL1 AFF1 CD4 CD7 CDKN2B ETV6
5 integument MP:0010771 9.81 ABCG2 CD19 CD4 CDKN2B CSF3 ETV6
6 liver/biliary system MP:0005370 9.5 ABCG2 ABL1 CD19 IKZF1 MTHFR PBX1
7 mortality/aging MP:0010768 9.47 ABL1 AFF1 CD19 CD4 CDKN2B CDX4

Drugs & Therapeutics for Adult Acute Lymphocytic Leukemia

Drugs for Adult Acute Lymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 143)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Cladribine Approved, Investigational Phase 4 4291-63-8 20279
Ifosfamide Approved Phase 4 3778-73-2 3690
Teniposide Approved Phase 4 29767-20-2 34698
Idarubicin Approved Phase 4 58957-92-9 42890
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Daunorubicin Approved Phase 4 20830-81-3 30323
Thioguanine Approved Phase 4 154-42-7 2723601
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
11 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
14 Molgramostim Investigational Phase 4 99283-10-0
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
16 Adjuvants, Immunologic Phase 4
Isophosphamide mustard Phase 4 0
18 Methylprednisolone Acetate Phase 4
19 Analgesics Phase 4
Lenograstim Approved, Investigational Phase 3 135968-09-1
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
Rasburicase Approved, Investigational Phase 3 134774-45-1
Allopurinol Approved Phase 3 315-30-0 2094
Epirubicin Approved Phase 3 56420-45-2 41867
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
26 N-Methylaspartate Phase 3
27 Antioxidants Phase 3
28 Rho(D) Immune Globulin Phase 3
29 gamma-Globulins Phase 3
30 Cyclosporins Phase 3
Mesna Approved, Investigational Phase 2 3375-50-6 598
alemtuzumab Approved, Investigational Phase 2 216503-57-0
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
Busulfan Approved, Investigational Phase 2 55-98-1 2478
Acyclovir Approved Phase 1, Phase 2 59277-89-3 2022
Sulfamethoxazole Approved Phase 1, Phase 2 723-46-6 5329
Levoleucovorin Approved, Investigational Phase 1, Phase 2 68538-85-2
Trimethoprim Approved, Vet_approved Phase 1, Phase 2 738-70-5 5578
Promethazine Approved, Investigational Phase 2 60-87-7 4927
Acetaminophen Approved Phase 2 103-90-2 1983
Mannitol Approved, Investigational Phase 2 69-65-8 6251 453
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
Benzyl alcohol Approved Phase 2 100-51-6 244
Ethanol Approved Phase 2 64-17-5 702
rituximab Approved Phase 2 174722-31-7 10201696
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
Idelalisib Approved Phase 1, Phase 2 870281-82-6
ofatumumab Approved Phase 2 679818-59-8 6918251
Ichthammol Approved Phase 2 8029-68-3

Interventional clinical trials:

(show top 50) (show all 81)
# Name Status NCT ID Phase Drugs
1 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
2 German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
3 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
4 Pilot Study for Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
5 Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
6 Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99) Completed NCT00199056 Phase 4 Dexamethasone / Prednisolone;Cyclophosphamide;Methotrexate;Vincristine / Vindesine;Daunorubicin;Asparaginase;G-CSF;Cytarabine;6-Mercaptopurine;VP16;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Ifosfamide
7 German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2) Completed NCT00199004 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Vincristine;Daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Adriamycin;Thioguanine;VM26;Rituximab
8 Prospective Study of Rituximab Combined With Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
9 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Completed NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
10 A Phase-2 Clinical Study to Determine the Efficacy and Safety of Depocyt (Cytarabine Liposome Injection) for the Treatment of CNS Relapse in Adult Patients With Acute Lymphoblastic Leukemia or Very Aggressive Lymphoma Unknown status NCT00199108 Phase 2, Phase 3 Depocyt;Dexamethasone
11 Randomized Controlled Trial to Test Efficacy of High-Dose Methotrexate Consolidation Therapy for BCR-ABL-Negative Acute Lymphoblastic Leukemia in Adults Unknown status NCT00131027 Phase 3 Cyclophosphamide;Daunorubicin;Vincristine;Prednisolone;L-asparaginase;Cytarabine;Etoposide;Dexamethasone;Methotrexate;Mercaptopurine;Doxorubicin;Methotrexate
12 Pegylated Liposomal Doxorubicin-contained Versus Daunorubicin-contained VDCLD Regimen in Previously Untreated Adult Patients With Acute Lymphoblastic Leukemia: Complete Remission Rates and Changes of Leukemia Stem Cells Unknown status NCT02070523 Phase 3 VDCLD regimen
13 Randomised Phase III Trial of Effectivity and Safety of Rasburicase Compared With Allopurinol for Treatment of Hyperuricemia in Patients With Acute Lymphoblastic Leukemia or High-Grade NHL With High Risk of Tumorlysis Syndrome (> 15 Yrs) Completed NCT00199043 Phase 3 Allopurinol;Rasburicase
14 Phase 3 Study of US-ATG-F to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients After Allogeneic Stem Cell Transplantation From Unrelated Donors Completed NCT01295710 Phase 3
15 A Prospective Study of Intensified Conditioning Regimen With High-Dose-Etoposide for Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia in China Completed NCT01457040 Phase 2, Phase 3 TBI+CY+VP-16;FA+TBI+CY+VP-16
16 Phase III Study to Compare Haplo-identical HSCT Versus Chemotherapy in First Remission for Standard-risk Adult Acute Lymphoblastic Leukemia Completed NCT02042690 Phase 3 Chemotherapy
17 A Randomized Study on CNS Prophylaxis With Liposome-Encapsulated Cytarabine in Association With a Lineage-Targeted and MRD-Oriented Postremission Strategy in Adult ALL Completed NCT00795756 Phase 2, Phase 3 liposome-encapsulated cytarabine (DepoCyte);Triple intrathecal therapy (TIT)
18 Open Label, Non-randomized, Phase II Study on Fractioned Cyclophosphamide, Vincristine, Liposomal Doxorubicin or Doxorubicin, and Dexamethasone (MY HYPER-CVAD) in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia Unknown status NCT00801580 Phase 2 doxorubicin liposomal
19 Phase 2 Study of Applying Pediatric Regimens to Younger Adult Patients With BCR-ABL-Negative Acute Lymphoblastic Leukemia Unknown status NCT00131053 Phase 2 Methotrexate;Prednisolone;Dexamethasone;Vincristine;Pirarubicin;Cyclophosphamide;L-asparaginase;Cytarabine;Hydrocortisone;Mercaptopurine
20 National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia With Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategy Unknown status NCT02067143 Phase 2 Prephase PDN + CY;Cycle 1 Induction;Cycle 2 Induction / Early consolidation;Cycle 3 Early consolidation;Cycle 4 Consolidation;Cycle 5 Consolidation;Cycle 6 Consolidation;Cycle 7 Consolidation;Cycle 8 Reinduction;Maintenance
21 A Phase I/II Study of Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia Unknown status NCT00983528 Phase 1, Phase 2 Clofarabine
22 DFCI ALL Adult Consortium Protocol: Adult ALL Trial Unknown status NCT01005758 Phase 2 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide phosphate;hydrocortisone sodium succinate;imatinib mesylate;mercaptopurine;methotrexate;methylprednisolone;pegaspargase;prednisolone;prednisone;vincristine sulfate
23 MULTICENTRE TRIAL OF INTENSIFIED THERAPY FOR ADULT ALL (O5/93) Unknown status NCT00002531 Phase 2 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;mercaptopurine;methotrexate;mitoxantrone hydrochloride;prednisolone;teniposide;thioguanine;vincristine sulfate;vindesine
24 German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary Failure Completed NCT00199030 Phase 2 Alemtuzumab (MabCampath);Cladribine
25 An Open-label, Phase 1/2 Study Of Inotuzumab Ozogamicin In Subjects With Relapsed Or Refractory Cd22-positive Acute Lymphocytic Leukemia Completed NCT01363297 Phase 2 Inotuzumab Ozogamicin
26 Phase I/II Study of Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia (ALL) or ALL in Relapse. Completed NCT00773149 Phase 1, Phase 2 Alemtuzumab (CAMPATH 1H) associated to G-CSF
27 Open-label, Multicenter Phase II Study to Investigate the Efficacy, Safety, and Tolerability of the Bispecific T-cell Engager (BiTE®) MT103 in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia Completed NCT00560794 Phase 2
28 A Confirmatory Multicenter, Single-arm Study to Assess the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (BLAST) Completed NCT01207388 Phase 2 Blinatumomab
29 An Open Label, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) Completed NCT01209286 Phase 2
30 GRAALL 2003 Trial (ALL 15-59 Years). Feasibility of Risk-Adapted Therapy in Young Adult Acute Lymphoblastic Leukemia: a Multicenter Trial Completed NCT00222027 Phase 2
31 Open Label Phase II Study to Evaluate the Safety of Standard Induction and Consolidation Therapy in Combination With Dasatinib in Newly Diagnosed Adult Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL) Completed NCT01724879 Phase 2 Dasatinib
32 An Escalating Dose Phase IIa Study of L-Asparaginase Encapsulated in Erythrocytes (GRASPA®) in Association With Polychemotherapy During Induction Phase for Treatment of Elderly Patients With Acute Lymphoblastic Leukaemia (ALL), Aged 55 Years and Over, With Philadelphia Chromosome-negative (ALL Ph-) Completed NCT01523782 Phase 2 GRASPA
33 "A Phase II Study With a Sequential Clofarabine-cyclophosphamide Combination Schedule as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) in Adult Patients" Completed NCT01462253 Phase 2 Clofarabine, Cyclophosphamide
34 Treatment of Adult Acute Lymphoblastic Leukemia Using a Post-remission Programme Whose Intensity Varies Depending on the Risk Class Defined on the Basis of Minimal Residual Disease. Completed NCT00358072 Phase 2
35 An Open Label, Multicenter, Phase II Study to Evaluate Efficacy and Safety of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) Completed NCT01466179 Phase 2
36 A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL) Completed NCT00061945 Phase 1, Phase 2 allopurinol;cyclophosphamide;daunorubicin hydrochloride;vincristine sulfate;dexamethasone;asparaginase;imatinib mesylate;methotrexate;cytarabine;trimethoprim-sulfamethoxazole;mercaptopurine;leucovorin calcium;acyclovir
37 Pre-administration of Rabbit Antithymocyte Globulin to Optimize Donor T-Cell Engraftment Following Reduced Intensity Allogeneic Peripheral Blood Progenitor Cell Transplantation From Matched-Related Donors Completed NCT00787761 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
38 A Phase 2 Multicenter Study of First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Completed NCT01004497 Phase 2 Dasatinib;Cyclophosphamide;Vincristine;Daunorubicin;Dexamethasone;Cytarabine;Mitoxantrone
39 Phase II Trial for the Treatment of Older Patients With Newly Diagnosed CD19 Positive, Ph/BCR-ABL Negative B-precursor Acute Lymphoblastic Leukemia With Sequential Dose Reduced Chemotherapy and Blinatumomab (EWALL-BOLD) Recruiting NCT03480438 Phase 2 Blinatumomab
40 Phase 1/2 Trial of TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Acute Lymphoblastic Leukemia (ALL) Recruiting NCT04323657 Phase 1, Phase 2 TC-110 T Cells;Fludarabine;Cyclophosphamide
41 Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Followed by Chemotherapy Consolidation and Maintenance Therapy In Patients Aged 56 Years and Older With Acute Lymphoblastic Leukemia (ALL) Recruiting NCT03460522 Phase 2 Inotuzumab ozogamicin
42 A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia Recruiting NCT01920737 Phase 2 Daunorubicin;Vincristine;Prednisone;PEG-Asparaginase;Methotrexate;6-MP (6-Mercaptopurine);Cyclophosphamide;Cytarabine;Leucovorin;Dexamethasone
43 Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults. A Phase II Trial Recruiting NCT03541083 Phase 2 Blinatumomab
44 Phase I-II Unmasked, Non-randomized Study Evaluating the Role of Idelalisib in Patients With Acute Lymphoblastic Leukemia (ALL) That is Relapsing or Refractory to Other Treatments, and in Older Patients With ALL for Whom Conventional Treatments Are Not Recommended Recruiting NCT03742323 Phase 1, Phase 2 Idelalisib
45 A Clinical Phase II Trial to Describe Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of Spectrila® With the Pharmaceutical Active Ingredient Recombinant L Asparaginase in Adult Subjects With Newly Diagnosed Acute B-Cell Lymphoblastic Leukaemia Recruiting NCT03156790 Phase 2 Spectrila®
46 A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies Recruiting NCT04033302 Phase 1, Phase 2
47 International Phase I/II Expansion Trial of the MEK Inhibitor Selumetinib in Combination With Dexamethasone for the Treatment of Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia Recruiting NCT03705507 Phase 1, Phase 2 Selumetinib;Dexamethasone
48 A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART19.1 in Patients With Relapsed or Refractory CD19 Positive B Cell Malignancies Recruiting NCT03853616 Phase 1, Phase 2
49 Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia Recruiting NCT02877303 Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Mercaptopurine;Methotrexate;Prednisone;Vincristine Sulfate
50 Chinese Children Cancer Group Relapsed Acute Lymphoblastic Leukemia 2017 Study Recruiting NCT04224571 Phase 2 Bortezomib Injection;rituximab injection

Search NIH Clinical Center for Adult Acute Lymphocytic Leukemia

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Adult Acute Lymphocytic Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Adult Acute Lymphocytic Leukemia:
Hematopoietic stem cells for treatment of hematologic malignancies
Peripheral blood stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Adult Acute Lymphocytic Leukemia:
Bone marrow-derived hematopoietic stem cells
Peripheral blood-derived hematopoietic stem cells (family)

Genetic Tests for Adult Acute Lymphocytic Leukemia

Anatomical Context for Adult Acute Lymphocytic Leukemia

MalaCards organs/tissues related to Adult Acute Lymphocytic Leukemia:

B Cells, T Cells, Bone, Bone Marrow, Myeloid, Testes, Lung
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Adult Acute Lymphocytic Leukemia:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
3 Blood Hematopoietic Bone Marrow Small Pre B-Cells Affected by disease

Publications for Adult Acute Lymphocytic Leukemia

Articles related to Adult Acute Lymphocytic Leukemia:

(show top 50) (show all 908)
# Title Authors PMID Year
Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. 54 61
15851765 2005
Associations between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma. 61 54
12604405 2003
Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. 61 54
11986237 2002
Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. 61 54
9041182 1997
The Clinical and Molecular Characteristics of FLT3 Mutations in Chinese De Novo Adolescent and Adult Acute Lymphoblastic Leukemia Patients. 61
32173273 2020
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. 61
32503572 2020
Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. 61
32469169 2020
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. 61
32467145 2020
Passet M, Boissel N, Sigaux F, et al; Group for Research on Adult ALL (GRAALL). PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. Blood. 2019;133(3):280-284. 61
32463891 2020
Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults. 61
32468488 2020
Prognostic significance of serum progranulin level in de novo adult acute lymphoblastic leukemia patients. 61
32006270 2020
Dendritic Cell Leukemia: a Review. 61
32415624 2020
Cerebral hemispheric glioblastoma with PNET-like morphology and histone H3.3 G34 mutation in younger patients: Report of three rare cases and diagnostic pitfalls. 61
32317528 2020
Education inequalities in adult all-cause mortality: first national data for Australia using linked census and mortality data. 61
31581296 2020
Effect of a 22q11.2 Microdeletion on Adult All-Cause Mortality in Tetralogy of Fallot Patients. 61
32348848 2020
At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial. 61
32220069 2020
Recent Advances in the Management of Acute Lymphoblastic Leukaemia. 61
32095902 2020
New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances. 61
31487068 2020
T-Cell Acute Lymphoblastic Leukemia: A Cytogenomic Update. 61
32526730 2020
Application of targeted next generation sequencing for the mutational profiling of patients with acute lymphoblastic leukemia. 61
32550823 2020
Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia. 61
32001801 2020
The Long Harm of Childhood: Childhood Exposure to Mortality and Subsequent Risk of Adult Mortality in Utah and The Netherlands. 61
31832028 2019
Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit? 61
31808881 2019
The clinical values of dysregulated DNA methylation and demethylation intermediates in acute lymphoblastic leukemia. 61
31315520 2019
Investigation of candidate molecular biomarkers for expression profile analysis of the Gene expression omnibus (GEO) in acute lymphocytic leukemia (ALL). 61
31606621 2019
Better survivals in adolescent and Young adults, compared to adults with acute lymphoblastic leukemia - A multicenter prospective registry in Thai population. 61
31675661 2019
Residual methylation of tumor suppressor gene promoters, RASSF6 and RASSF10, as novel biomarkers for minimal residual disease detection in adult acute lymphoblastic leukemia. 61
31486880 2019
Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. 61
31340073 2019
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. 61
31446198 2019
Clinicians' Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study. 61
31586302 2019
Recent advances in the treatment of acute lymphoblastic leukemia. 61
31092071 2019
Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia. 61
31717700 2019
TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia. 61
31376919 2019
ARID5B rs10821936 and rs10994982 gene polymorphisms and acute lymphoblastic leukemia: relation to disease susceptibility and outcome. 61
31424309 2019
Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia. 61
31132205 2019
Outcomes of adult acute lymphoblastic leukemia in the era of pediatric-inspired regimens: a single-center experience. 61
31161483 2019
Chromosomal microarray analysis is superior in identifying cryptic aberrations in patients with acute lymphoblastic leukemia at diagnosis/relapse as a single assay. 61
31112375 2019
EXT1, Regulated by MiR-665, Promotes Cell Apoptosis via ERK1/2 Signaling Pathway in Acute Lymphoblastic Leukemia. 61
31465316 2019
Survival in adult acute lymphoblastic leukaemia (ALL): A report from the Swedish ALL Registry. 61
31074910 2019
The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. 61
30916384 2019
Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL. 61
30635636 2019
Prolonged lumbosacral pain as the initial presentation in acute lymphoblastic leukemia in an adult: A case report. 61
31192927 2019
[Clinical Features and Therapeutic Efficacy in Adult Acute Lymphoblastic Leukemia with t (1; 19) (E2A-PBX1)]. 61
31204910 2019
The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response. 61
31064074 2019
Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia. 61
30322332 2019
The Impact of Low-Dose Cranial Boost on the Long-Term Outcomes of Adult Patients with High-Risk Acute Lymphoblastic Leukemia Undergoing Total Body Irradiation and Allogeneic Hematopoietic Stem Cell Transplantation. 61
30578956 2019
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. 61
31110096 2019
Detection of a cryptic NUP214/ABL1 gene fusion by mate-pair sequencing (MPseq) in a newly diagnosed case of pediatric T-lymphoblastic leukemia. 61
30936193 2019
Clinical and genetic characterization of de novo double-hit B cell precursor leukemia/lymphoma. 61
30613837 2019
Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. 61
30764841 2019

Variations for Adult Acute Lymphocytic Leukemia

Expression for Adult Acute Lymphocytic Leukemia

Search GEO for disease gene expression data for Adult Acute Lymphocytic Leukemia.

Pathways for Adult Acute Lymphocytic Leukemia

GO Terms for Adult Acute Lymphocytic Leukemia

Biological processes related to Adult Acute Lymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.76 TP73 PBX1 IKZF1 ETV6 CSF3 CDX4
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.65 CSF3 CD4 ABL1
3 cell cycle arrest GO:0007050 9.62 TP73 CDKN2B CDKN1C ABL1
4 methionine biosynthetic process GO:0009086 9.46 MTR MTHFR
5 response to folic acid GO:0051593 9.43 TYMS MTHFR
6 spleen development GO:0048536 9.43 PBX1 CDKN2B ABL1
7 B cell proliferation involved in immune response GO:0002322 9.4 CD19 ABL1
8 dTMP biosynthetic process GO:0006231 9.37 TYMS SHMT1
9 tetrahydrofolate interconversion GO:0035999 9.13 TYMS SHMT1 MTHFR
10 tetrahydrofolate metabolic process GO:0046653 8.8 TYMS SHMT1 MTHFR

Molecular functions related to Adult Acute Lymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.43 TP73 PBX1 IKZF1 ETV6 CDX4 AFF1
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CDKN2B CDKN1C

Sources for Adult Acute Lymphocytic Leukemia

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....